Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Phase 1

Recruiting

Conditions: Gastrointestinal Cancer

Interventions: Drug: Capecitabine
Drug: Sacituzumab govetican

First Posted Date: 2023-10-03

Last Posted Date: 2024-12-09

Lead Sponsor: Henry Ford Health System

Target Recruit Count: 20

Registration Number: NCT06065371

Locations: 🇺🇸
Henry Ford Cancer-Detroit, Detroit, Michigan, United States

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Phase 2

Not yet recruiting

Conditions: Locally Advanced Rectal Cancer

Interventions: Drug: capecitabine
Drug: tislelizumab
Drug: thymalfasin
Radiation: long-term radiotherapy

First Posted Date: 2023-09-28

Last Posted Date: 2023-11-18

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 20

Registration Number: NCT06056804

Locations: 🇨🇳
Beijing Friendship Hospital,Capital Medical University, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, China

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Solid Tumor

Interventions: Drug: QLS31905
Drug: Oxaliplatin
Drug: Nab paclitaxel
Drug: Gemcitabine
Drug: Capecitabine
Drug: Cisplatin

First Posted Date: 2023-09-18

Last Posted Date: 2023-09-18

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 115

Registration Number: NCT06041035

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Phase 2

Recruiting

Conditions: Biliary Tract Cancer
Cholangiocarcinoma

Interventions: Drug: Gemcitabine
Drug: Nab paclitaxel
Drug: Cisplatin
Procedure: Curative Surgery
Drug: Capecitabine

First Posted Date: 2023-09-14

Last Posted Date: 2023-11-15

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 300

Registration Number: NCT06037980

Locations: 🇮🇹
Humanitas Cancer Center, Milan, Italy
🇮🇹
Azienda Ospedaliera Universitaria Pisa, Pisa, Italy
🇮🇹
ASST Spedali Civili, Brescia, Italy

and more 16 locations

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Phase 3

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: DB-1303/BNT323
Drug: Capecitabine
Drug: Paclitaxel
Drug: Nab-paclitaxel

First Posted Date: 2023-08-30

Last Posted Date: 2024-11-26

Lead Sponsor: DualityBio Inc.

Target Recruit Count: 532

Registration Number: NCT06018337

Locations: 🇺🇸
Research Site 1141-0, Tucson, Arizona, United States
🇺🇸
Research Site 1114-0, Fullerton, California, United States
🇺🇸
Research Site 1107-0, Los Angeles, California, United States

and more 182 locations